bild

The logo of Swiss biopharmaceutical company Debiopharm is pictured at the Research and Manufacturing center during the coronavirus disease (COVID-19) outbreak, in Martigny, Switzerland, Sunday, January 17, 2021. Debiopharm announces the launch of phase II research of its antiviral drug Alisporivir, which could provide new treatment perspectives against Covid-19. (KEYSTONE/Laurent Gillieron)